drugset / Trial / NCT03765775
Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative
NaSingle-groupOpen-labelTreatment
Summary
This is an efficacy and safety study of Anlotinib combined with Sintilimab (IBI 308) in participants with advanced or metastatic non-small cell lung cancer (NSCLC) who have received first-generation EGFR-TKIs resistance along with T790M negative.
Timeline
- Start
- 2018-11-20
- Primary completion
- 2019-12-31
- Completion
- 2021-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 10 mg | Oral |
| Subject | Sintilimab | Monoclonal antibody | 200 mg | Intravenous |